CareDx, Inc.

Day range

$68.33 – $70.31

Open

$68.87

Prev close

$69.21

Volume

321.61K

Market cap

$3.58B

Shares out

51.73M

P/E

32.25

P/S

7.82

P/B

8.41

P/FCF

42.27

ROE

26.1%

ROA

20.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationJul 30, 2026

  The Company is posting an updated corporate presentation (the "Corporate Presentation") on its website. The Corporate Presentation is current as of June 30, 2026.

• Acquisition completionJul 7, 2026

  On July 1, 2026, the Company and Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), completed the previously announced acquisition of Naveris, Inc., a Delaware corporation ("Naveris")... The aggregate purchase price paid by the Company consisted of $161.8 million in cash, subject to certain customary adjustments specified in the Merger Agreement for Naveris' cash, indebtedness, transaction expenses and net working capital. Additionally, under the terms and subject to the conditions set forth in the Merger Agreement, Naveris' equityholders will be eligible to receive up to $100.0 million in additional cash consideration contingent upon the achievement of specified revenue-based milestones in respect of fiscal years ending December 31, 2026 and December 31, 2027.

• Director appointmentJun 15, 2026

  To elect Fred E. Cohen, M.D., D. Phil, R. Bryan Riggsbee and Suresh Gunasekaran as Class II directors, and Michael D. Goldberg and John W. Hanna as Class III directors, each to serve a one-year term, which will expire at the 2027 Annual Meeting of Stockholders... Each of the five nominees for director was elected to serve until the Company's 2027 annual meeting of stockholders.

• Acquisition agreementApr 28, 2026

  On April 28, 2026, CareDx, Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Naveris, Inc., a Delaware corporation ("Naveris"), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders of Naveris, pursuant to which, and subject to the terms and conditions set forth therein, Merger Sub will merge with and into Naveris, with Naveris continuing as the surviving corporation and a wholly owned subsidiary of the Company (the "Transaction"). Under the terms and subject to the conditions set forth in the Merger Agreement, at the closing of the Transaction (the "Closing"), the Company will pay to Naveris' equityholders an aggregate $160.0 million in cash, subject to certain customary adjustments specified in the Merger Agreement, including for Naveris' cash, indebtedness, transaction expenses and net working capital. Additionally, under the terms and subject to the conditions set forth in the Merger Agreement, Naveris' equityholders will be eligible to receive up to $100.0 million in additional cash consideration contingent upon the achievement of specified revenue-based milestones in respect of fiscal years ending December 31, 2026 and December 31, 2027.

• Preliminary resultsApr 16, 2026

  On April 15, 2026, the Company issued a press release (the "Press Release"), as described further under Item 7.01 below, which included information with respect to the Company's preliminary unaudited financial results for the quarter ended March 31, 2026 and certain additional preliminary metrics.

Days to cover

4.6

Short interest

6.59M

Avg volume

1.44M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
  neutralZacks Investment Research· Oct 26, 2026
• Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR
  positiveGlobeNewswire Inc.· Oct 5, 2026
• Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
  positiveZacks Investment Research· Sep 30, 2026
• 4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
  positiveZacks Investment Research· Sep 14, 2026
• Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
  positiveZacks Investment Research· Sep 9, 2026